OA16526A - Sildenafil-free base-containing film preparation and method for producing same. - Google Patents
Sildenafil-free base-containing film preparation and method for producing same. Download PDFInfo
- Publication number
- OA16526A OA16526A OA1201300334 OA16526A OA 16526 A OA16526 A OA 16526A OA 1201300334 OA1201300334 OA 1201300334 OA 16526 A OA16526 A OA 16526A
- Authority
- OA
- OAPI
- Prior art keywords
- free base
- film
- sildenafil free
- polymer
- sildenafil
- Prior art date
Links
- 239000012458 free base Substances 0.000 title claims abstract description 73
- 238000002360 preparation method Methods 0.000 title description 3
- 238000004519 manufacturing process Methods 0.000 title description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N Sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims abstract description 78
- 229960003310 sildenafil Drugs 0.000 claims abstract description 78
- 239000002245 particle Substances 0.000 claims description 57
- 229920000642 polymer Polymers 0.000 claims description 47
- 239000000203 mixture Substances 0.000 claims description 27
- 239000000243 solution Substances 0.000 claims description 26
- 238000009826 distribution Methods 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000002270 dispersing agent Substances 0.000 claims description 13
- 239000004094 surface-active agent Substances 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 12
- 239000004014 plasticizer Substances 0.000 claims description 11
- 239000004373 Pullulan Substances 0.000 claims description 9
- 229920001218 Pullulan Polymers 0.000 claims description 9
- 235000019423 pullulan Nutrition 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- 230000000875 corresponding Effects 0.000 claims description 8
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 claims description 6
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 claims description 6
- 239000000770 propane-1,2-diol alginate Substances 0.000 claims description 6
- 239000000230 xanthan gum Substances 0.000 claims description 6
- 235000010493 xanthan gum Nutrition 0.000 claims description 6
- 229920001285 xanthan gum Polymers 0.000 claims description 6
- 229940082509 xanthan gum Drugs 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 238000000265 homogenisation Methods 0.000 description 17
- 238000009472 formulation Methods 0.000 description 14
- 238000000576 coating method Methods 0.000 description 9
- 239000011248 coating agent Substances 0.000 description 8
- 230000014860 sensory perception of taste Effects 0.000 description 8
- 235000019640 taste Nutrition 0.000 description 8
- 230000035917 taste Effects 0.000 description 8
- 239000000654 additive Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 230000000996 additive Effects 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 229960002639 Sildenafil citrate Drugs 0.000 description 4
- -1 caraginane Polymers 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 2
- APSBXTVYXVQYAB-UHFFFAOYSA-M Dioctyl sodium sulfosuccinate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 2
- 229960000878 Docusate Sodium Drugs 0.000 description 2
- 206010013911 Dysgeusia Diseases 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229940068968 Polysorbate 80 Drugs 0.000 description 2
- 229940005550 Sodium alginate Drugs 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 230000003247 decreasing Effects 0.000 description 2
- 238000007872 degassing Methods 0.000 description 2
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- BAQAVOSOZGMPRM-JVFSCRHWSA-N (2R,3R,4R,5R,6R)-2-[(2S,3R,4R,5R)-2,5-bis(chloromethyl)-3,4-dihydroxyoxolan-2-yl]oxy-5-chloro-6-(hydroxymethyl)oxane-3,4-diol Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@]1(CCl)[C@H](O)[C@@H](O)[C@H](CCl)O1 BAQAVOSOZGMPRM-JVFSCRHWSA-N 0.000 description 1
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 description 1
- 229960001631 Carbomer Drugs 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 206010053317 Hydrophobia Diseases 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 210000002200 Mouth Mucosa Anatomy 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 229960000502 Poloxamer Drugs 0.000 description 1
- 239000004698 Polyethylene (PE) Substances 0.000 description 1
- 229940068965 Polysorbates Drugs 0.000 description 1
- 229940068984 Polyvinyl Alcohol Drugs 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229940069328 Povidone Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N Saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- JNYAEWCLZODPBN-CTQIIAAMSA-N Sorbitan Chemical class OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000002542 deteriorative Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 230000002349 favourable Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 238000011068 load Methods 0.000 description 1
- 229920003113 low viscosity grade hydroxypropyl cellulose Polymers 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001888 polyacrylic acid Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 238000004642 transportation engineering Methods 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Abstract
The present invention provides a method for preparing a film comprising a high amount of a sildenafil free base uniformly dispersed therein and having a suitable thickness and size, as well as flexibility providing good handling stability and being not prone to breaking. The present invention also provides a sildenafil free basecontaining film prepared from the method.
Description
The présent invention relates to a sildenafil free base-containing film formulation for oral administration and a method for preparing the same.
BACKGROUND ART
Sildenafil is a représentative therapeutic agent among various commercially available agents for treating erectile dysfunction, and it has been commercially available in the form of a tablet formulation containing sildenafil citrate.
When having to use therapeutic agents for erectile dysfunction, in terms of transportability, it is préférable to use film forms, which are often called strips.
However, sildenafil citrate is commercially available in 25, 50 or 100 mg sildenafil citrate-containing tablets, but due to a high single dose, it is not feasible to formulate in a film form. Specifically, the total weight of commercially available film formulations is mostly in the range of 30 to 100 mg, and an active ingrédient containing a high dose is difficult to formulate in a film form for the following reasons:
First, in the préparation of a film formulation, a fixed amount of polymer or more must essentially be used to maintain the form of a film. However, in order to load a high amount of an effective ingrédient in a limited film size, the amount of such a polymer can only reduce. In the case the amount of polymer is not sufficient, the formed film may not have the desired properties (e.g., flexibility and tension) for handling.
Second, to contain a high amount of active ingrédient in a film, the inhérent properties of an active ingrédient must be overcome. However, if the amount of additives is restricted, it is difficult to offset the inhérent properties. Furthermore, if an active ingrédient is not dissolved but just dispersed or suspended in the film-making solution, the Iayer séparation of the film-making solution or the non-homogenization of the active ingrédient may occur. Such a Iayer séparation or non-homogenization may also occur during préparation of the film-making solution, transportation of the solution for coating, and coating and drying processes. v/***
Third, it is general to increase the viscosity of a solution or suspension for forming a film in the préparation of a film containing a dispersed or suspended active ingrédient in a high amount. However, an excessive viscosity may adversely affect the characteristics and quality of a dried film. Accordingly, high viscosity may be a drawback in terms of good production.
DISCLOSURE
Technical Problem
The présent invention is designed to solve the problème of the prior art, and therefore it is an object of the présent invention to provide a film or strip comprising sildenafil or a pharmaceutically acceptable sait thereof in a high amount and having a thickness and size suitable for administration as well as good handling and superior properties, and a method for preparing the film or strip.
Technical Solution
In order to accomplish the object of the présent invention, in accordance with one aspect of the présent invention, there is provided a method for preparing a sildenafil free base-containing film, comprising drying a polymer solution in which a sildenafil free base as an active ingrédient is dispersed (substantially not dissolved).
The commercially available sildenafil citrate is not suitable for preparing a film formulation by way of dispersion or suspension because it can dissolve in water and also exhibit a bitter taste in the mouth. Accordingly, the présent inventors hâve endeavored to develop a new form of sildenafil suitable in a film formulation and found that a sildenafil free base is practically insoluble in water, thereby accomplishing the desired object of the présent invention, and exhibits no taste in the mouth, making the sildenafil free base suitable to be used in a film formulation.
Also, the présent inventors hâve found that when the sildenafil free base is suspended (dispersed) without the substantial dissolution thereof in a polymer solution to form a film, the formed film can still hâve the desired properties even though the sildenafil free base is used in a high amount.
In the présent invention, the term “suspended without the substantial dissolution” means that the sildenafil free base is dissolved in an amount of 15 wt% or less, preferably 10 wt%, more preferably 7 wt%, still more preferably 4 wt%, most preferably 2 wt%, based on the total weight thereof.
In the film formulation according to the présent invention, the sildenafil free base is not substantially dissolved, which restricts the interaction with a polymer used for forming a film. From this, it is expected that the formed film exhibits the desired properties even though the film comprises a high amount of the sildenafil free base, but the présent invention is not limited thereto.
In the présent invention, the film may be called a strip, orally dissolving film or orally disintegrating film, and refers to a formulation adminîstered by attaching and melting the film on top and below the tongue, oral mucosa and in the mouth. The film formulation according to the présent invention has an advantage in that it can be adminîstered without water.
Preferably, the sildenafil free base used in the method of the présent invention has a particle size distribution in which a particle diameter (DIO) corresponding to 10% of the distribution is 10 pm or more and a particle diameter (D90) corresponding to 90% of the distribution is 150 pm or less. More preferably, the sildenafil free base has a particle size distribution in which DIO is 8 pm or more and D90 is 100 pm or less, still more preferably a particle size distribution in which DIO is 5 pm or more and D90 is 80 pm or less.
In the method of the présent invention, the sildenafil free base having a uniform particle size distribution is only used to be stably dispersed and suspended in a film préparation, from which physical stabilîty can be obtained in a film préparation using a low viscosity polymer, thereby improving the processibility of the film. Also, the use of the sildenafil free base having such a particle size distribution in the préparation of the film can provide good characteristics and properties to the film prepared.
For example, if the sildenafil free base used has a particle size distribution exceeding the above-mentioned range, the particles of the sildenafil free base are observed in the film prepared and the film has a rough surface. Also, such a sildenafil free base can easily precipitate during the préparation process, which increases the likelihood of ununiform distribution.
More specifically, when a sildenafil free base having a particle size distribution, wherein D90 is more than 150 pm is used in a film préparation having a low viscosity, particles are visually observed in the film prepared, and the sildenafil free base is precipitated in the film préparation having a viscosity of 4,000 to 8,000 cp within one day, thereby exhibiting poor physical stability.
In order to overcome this problem, i.e., to maintain the suspension stability of the sildenafil free base during the préparation process, it is necessary to increase the viscosity of a film préparation, but the following problems may occur. First, the use of a film préparation having a high viscosity may cause an ununiform coating density in the coating thereof, thereby resulting in the ununiform density (weight) and content of each film unit. Second, it is difficult to carry out a degassing process which is considered as being essential in the préparation of a filin. Third, the use of an additional solvent is inevitably required to overcome the problem due to the high viscosity of the film préparation, however, it may reduce the dispersion stability of the sildenafil free base, and may raise a coating thickness due to an increased amount of solvents, thereby deteriorating the physical stability of the film préparation during a drying procedure after coating. Also, the increase of the coating thickness may cause poor drying results which refers to the génération of cracks or wrinkles on the film prepared.
On the contrary, if the sildenafil free base has a particle size distribution in which DIO is 5 μιη or less, the solubility of the sildenafil free base may rapidly increase, which may make it difficult to achieve the object of the présent invention, that is by way of dispersion or suspension, and the sildenafil free base may agglomerate. Also, the absorption patterns (e.g., Cmil!t, Tmaj[) of the sildenafil free base may become unpredictable.
In the method of the présent invention, it is preferred that a solvent used in the polymer solution comprises water in an amount of 90 wt% or more, preferably 95 wt% or more, more preferably 98 wt% or more thereof so that the sildenafil free base is prevented from being dissolved.
More preferably, the présent invention provides a method for preparing a sildenafil free base-containing film, comprising dispersing a sildenafil free base in a solution obtained by dissolving a polymer and a plasticizer in a solvent comprising 90 wt% or more of water, and drying the solution to form a dried film, the sildenafil free base having a particle size distribution in which DIO is 5 pm or more and D90 is 80 μιη or less, wherein the polymer is used in an amount of 20 to 45 wt%, the plasticizer is used in an amount of 4 to 20 wt%, and the sildenafil free base is used in an amount of 40 to 60 wt%, based on the total weight of the dried film.
In the présent invention, it is preferred that the polymer used for forming a film has a viscosity of 15 cp or less (preferably l to 15 cp) when measured in an aqueous solution containing 2 wt% of the polymer. When the viscosity of the polymer satîsfies such a range, the préparation of the film can be easily performed, and the formed film can hâve the desired properties and can be rapidly disintegrated in the mouth. Examples of the polymer having a viscosity of 15 cp or less include pullulan, low viscosity hydroxypropyl cellulose, low viscosity hydroxypropylmethyl cellulose, etc.
In the présent invention, in order to increase the strength of the film, a small amount of a polymer having a viscosity of 50 cp or more (preferably 50 to 10,000 cp) when measured in an aqueous solution containing 2 wt% of the polymer may be used together with the above-mentioned polymer having a viscosity of 15 cp or less. In this case, the polymer having a viscosity of 50 cp or more is used in an amount of 20 wt% or less, preferably 10 wt% or less, more preferably 5 wt% or less, most preferably 3 wt% or less, based on the total weight of the film after drying. Examples of the polymer having a viscosity of 50 cp or more include xanthan gum, propylene glycol alginate, sodium alginate, alginic acid, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, guar gum, sodium carboxymethyl cellulose, etc.
The polymer for forming the film which may be used in the présent invention include pullulan, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, xanthan gum, sodium alginate, propylene glycol alginate, povidone, poloxamer, polyvinyl alcohol, alginic acid, caraginane, polyethylene oxide, carbomer, calcium carboxymethyl cellulose, sodium carboxymethyl cellulose, gelatin, hydroxyethyl cellulose and a mixture thereof. Among these, pullulan is preferred, and a mixture of pullulan, propylene glycol alginate and xanthan gum is most preferred, in terms of the compatibility with the sildenafil free base used as an active ingrédient.
Considering the viscosity and content of the polymer used and the object of the présent invention, it is preferred that the film préparation has a viscosity of 4,000 to
8,000 cp, more preferably 5,000 to 8,000 cp, most preferably 5,000 to 6,000 cp.
The plasticizer comprised in the film préparation of the présent invention may be glycerin, sorbitol, polyethylene glycol, propylene glycol, triethyl citrate or a mixture thereof.
Preferably, the film préparation of the présent invention further comprises a surfactant and/or a dispersing agent. In the method of the présent invention, the surfactant and/or dispersing agent may be effectively added, thereby more stably dispersing the sildenafil free base between the polymer chain as compared to a simply suspended dispersion solution and ensuring the physical stability of the active ingrédient in the film préparation. That is, the surfactant and/or dispersing agent may be used to reduce layer séparation and agglomération between active ingrédient particles which are hydrophobie. Each of the surfactant and/or the dispersing agent is preferably used in an amount of O.l to 2 wt% based on the total weight of the film préparation.
Examples of the surfactant and/or dispersing agent which may be used in the présent invention include polysorbates, polyoxyethylene alkyl ethers, polyoxyethylene castor oil, polyoxyethylene stéarate, docusate sodium, sodium lauryl sulfate, sorbitan esters and a mixture thereof. Among these, polysorbate 80 is most preferred in terms of the object of the présent invention, in particular, the interaction with other components used.
In the film préparation, the solvent is used in an amount of 0.7 to 4 parts by weight, preferably 1.3 to 3.3 parts by weight based on l part by weight of the components of the film remained after drying, considering various aspects including the thickness of the film according to the coating of the film préparation, drying speed, and the viscosity of the film préparation.
Further, the présent invention provides a sildenafil free base-containing film, comprising a sildenafil free base uniformly dispersed in a film comprising pullulan as a polymer, the sildenafil free base having a particle size distribution in which a particle diameter (DIO) corresponding to 10% of the distribution is 8 pm or more and a particle diameter (D90) corresponding to 90% of the distribution is 100 pm or less.
Preferably, the sildenafil free base-containing film comprises glycérine as a plasticizer. More preferably, the film further comprises a surfactant (preferably polysorbate 80) and/or a dispersing agent (preferably, docusate sodium).
The sildenafil free base-containing film according to the présent invention has a thickness of 40 to 200 pm, preferably 60 to 150 pm, more preferably 80 to 120 pm„
Advantageous Effects
In accordance with the présent invention, provided is a method for preparing a film comprising a high amount of a sildenafil free base uniformly dispersed therein and having a suitable thickness and size, as well as flexibility providing good handling stability and being not prone to breaking. The présent invention also provides a sildenafil free base-containing film prepared from the method.
BEST MODE
Hereinafter, various preferred examples of the présent invention will be described in detail for better understanding. However, the examples of the présent invention may be modified in various ways, and they should not be interpreted as limiting the scope of the invention. The examples of the présent invention are just for better understanding of the invention to persons having ordinary skill in the art.
<Measurement of Particle Size and Characteristic Change Depending on the rpm Variation of Homogenizer>
A préparative expérimentation was conducted to analyze the particle size of a sildenafil free base and the characteristics thereof in several film préparations depending on the rpm conditions (3,000 or 5,000 rpm) of a homogenizer (AGI homomixer) and homogenization times (0, 10 and 30 minutes), the film préparations having the same compositions as the Examples shown in Table 6.
First, the raw materials of a sildenafil free base before homogenization were measured for their particle size using Mastersizer 2000 (Malvem) by a wet method, and the results thereof are shown in Table l. The same procedure was repeated three times.
Table 1
Formulation | D10(pm) | D90 (μιη) |
1 (Example 1) | 13.34 | 283.16 |
2 (Example 2) | 13.77 | 279.83 |
3 (Example 3) | 13.33 | 282.22 |
Particle size variation results after homogenization are shown in Table 2.
Table 2
Conditions | Particle size (pm) | Characteristics | ||
D10 | D90 | |||
Initial | 13.48 | 281.74 | - | |
3000 rpm | 10 minutes (Example 4) | 10.23 | 115.56 | Particles were visually observed |
30 minutes | 8.91 | 109.66 | Particles were visually observed | |
5000 rpm | 10 minutes | 8.59 | 85.99 | Particles were scarcely observed visually |
30 minutes (Example 5) | 8.06 | 67.80 | No particle was observed visually |
Meanwhile, in the case that propylene glycol alginate was further added and homogenization was carried out under the same conditions as Example 4, DIO and D90 in particle size distribution were 10.83 pm and 116.34 pm, respectively (Example 6).
<Measurement of Particle Size Change Depending on Homogenization Times>
The particle size changes of a sildenafil free base depending on homogenization times were measured under the condition of a larger scale than the previous expérimentation. The homogenization was carried out using a homogenizer (IKA) at 5,000 rpm with increasing homogenization time. The sildenafil free base-containing film préparations used in the homogenization had the same compositions as the Examples shown in Table 6. The measurement results are shown in Table 3.
Table 3
Conditions and Samples | Particle size (pm) | ||
D10 | D90 | ||
Initial | 13.48 | 281.74 | |
Scale up -1 (Example 8) | 30 minutes | 8.64 | 82.84 |
60 minutes | 8.34 | 78.21 | |
90 minutes | 8.15 | 75.89 | |
120 minutes | 7.99 | 71.17 | |
Scale up - 2 (Example 9) | 30 minutes | 8.19 | 79.21 |
60 minutes | 7.96 | 74.23 | |
90 minutes | 7.31 | 69.60 | |
120 minutes | 7.55 | 68.14 | |
Scale up - 3 (Example 10) | 30 minutes | 8.83 | 83.30 |
60 minutes | 8.35 | 76.49 | |
90 minutes | 8.09 | 72.80 | |
120 minutes | 7.99 | 71.69 |
<Preparation of Film Having Minimized Particle Sîze>
In order to préparé films containing sildenafil free base particles having a φ/' smaller size, the film préparation having the same compositions as the Example 8 shown în Table 6 were subject to homogenization using a homogenizer (IKA) at 10,000 rpm for 1 hour. The measurement results are shown in Table 4.
Table 4
Conditions | Particle Sizei | uni) | Characteristics | ||
D10 | D50 | D90 | |||
10,000 rpm | 30 minutes (Example 11) | 2.18 | 18.79 | 50.41 | No particle was observed. Semitransparent film |
60 minutes (Example 12) | 1.36 | 5.39 | 25.70 | No particle was observed. Semitransparent film Transparency increase as compared to Example 11 |
As shown in Table 4, after homogenization at 10,000 rpm for 30 and 60 minutes, the numerical values of D10/D90 were 2.18/50.41 and 1.36/25.70, respectively, which hâve significantly decreased as compared to particle sizes obtained after homogenization at 5,000 rpm. Also, as the particle size decreased, the transparency of the finished film increased.
<Evaluation for Property Stability of Film Préparation by Particle Size>
In order to observe whether the film préparations previously obtained caused layer séparation thereof or not, and evaluate the characteristics of the film prepared, each sample was taken from the upper part and the lower part of the film préparations to préparé a film, and each unit weight thereof was measured. The results thereof are shown in Table 5. 'J''
Table 5
Elapsed Time | Properties | Samples | Weight Différence Between Upper Part/Lower Part | ||
Example 4 | Example 10 | Example 4 | Example 10 | ||
1 Day | Layer Séparation | No | No | - | - |
Characteristics (Film) | Particles were observed on the surface of the film | No particle was observed on the surface of the film | |||
Unit Weight | Upper | 99.8 mg | 100.9 mg | 0.3 mg | |
Lower | 100.1 mg | 100.4 mg | |||
3 Days | Layer Séparation | No | No | - | - |
Characteristics (Film) | Particles were observed on the surface of the film | No particle was observed on the surface of the film | |||
Unit Weight | Upper | 97.1 mg | 101.4 mg | 6.5 mg | |
Lower | 103.6 mg | 101.2 mg | |||
7 Days | Layer Séparation | No | No | - | - |
Characteristics (Film) | Particles were observed on the surface of the film | No particle was observed on the surface of the film | |||
Unit Weight | Upper | 93.3 mg | 101.9 mg | 13.5 mg | |
Lower | 106.8 mg | 102.2 mg |
In Table 5, the characteristics refer to those of the film prepared, and the unit weight refers to a weight (mg) per unit area (9.99 cm ) of the film prepared.
The film préparation of Example 4 in which the particle sizes of D10 and D90 were 10.23 pm and 115.56 pm, respectively, exhibited poor stability including layer séparation as time passed. For this reason, the ratio of the lower part relative to the upper part in the film préparation increased, thereby leading to an increase in unit weight after drying.
<Preparation of Sildenafil Free Base-Containing Film Formulation>
Film formulations were prepared according to the method and compositions shown in Table 6 as follows.
Examples 11 and 12: A plasticizer, an additive, a sweeting agent, a surfactant and a dispersing agent were added to purified water, followed by dîssolvîng or dispersing by stirring, to which a sildenafil free base was added. Then, homogenization was carried out using a homogenizer (Ultra turrax T-25, IKA) at
10,000 rpm for 30 and 60 minutes, respectively. Thereto, a polymer was added and — again homogenized using the same homogenizer to obtain a polymer solution having the sildenafil free base dispersed therein. To the polymer solution, a flavor was added and mixed by stirring. Then, the resulting film préparation was subject to degassing under vacuum at 45 °C, cooled to room température, and then coated on a PE film in a suitable thickness. The coating was dried at 80 °C to obtain a sildenafil free basecontaining film formulation.
Examples 5, 7, 8, 9 and 10: A plasticizer, an additive, a sweeting agent, a surfactant and a dispersing agent were added to purified water, followed by dissolving or dispersing by stirring, to which a sildenafil free base was added. Then, homogenization was carried out using a homogenizer (Ultra turrax T-25, IKA) at 5,000 rpm for 30 minutes. Thereto, a polymer was added and again homogenized using the same homogenizer to obtain a polymer solution having the sildenafil free base dispersed therein. Then, the same procedure of Example 11 was repeated to obtain a sildenafil free base-containing film formulation.
Examples 4 and 6: A plasticizer, an additive, a sweeting agent, a surfactant and a dispersing agent were added to purified water, followed by dissolving or dispersing by stirring, to which a sildenafil free base was added. Then, homogenization was carried out using a homogenizer (Ultra turrax T-25, IKA) at 3,000 rpm for 10 minutes. Thereto, a polymer was added and again homogenized using the same homogenizer to obtain a polymer solution having the sildenafil free base dispersed therein. Then, the same procedure of Example 11 was repeated to obtain a sildenafil free base-containing film formulation.
Examples 1, 2 and 3: A plasticizer, an additive, a sweeting agent, a surfactant and a dispersing agent were added to purified water, followed by dissolving or dispersing by stirring, to which a sildenafil free base was added. Subsequently, the résultant was stirred for a certain time and a polymer was added thereto, followed by stirring again. Then, the same procedure of Example 11 was repeated to obtain a sildenafil free base-containing film formulation. —
Table 6
Ingrédients | Example (Unit: wt%) | ||||||||||||
1 | 2 | 3 | 4 | 5 | 8 | 7 | 8 | 9 | io | 11 | 12 | ||
O10 (lim) D90 (um) | 13.34 283.16 | 13.77 279.83 | 13.33 282.22 | 10.23 115.58 | 8 06 67.80 | 10.83 116.34 | 10.74 69.99 | 7.99 71.17 | 7.55 68.14 | 7.99 71.89 | 2.18 50.41 | 1.38 25.70 | |
API | SildenafH | 23.54 | 15.79 | 21.93 | 23.15 | 23.28 | 24.39 | 15.48 | 14 94 | 15.01 | 15.15 | 15.01 | 15.15 |
Polymer | Pullutan | 7.CB | 3.30 | 5.28 | 8.48 | 8.05 | 8.34 | 9.29 | 9.34 | 9.31 | 9.25 | B.31 | 9.25 |
Propylene glycol alglnatc | - | 1.28 | 0.88 | - | - | 0.49 | 0.82 | 0.86 | 0.68 | 0.69 | 0.88 | 0.89 | |
Xanthan gum | 0.04 | 0.08 | 0.07 | 0.07 | 0.05 | 0.04 | 0.06 | 0.08 | 0.02 | 0.01 | 0.02 | 0.01 | |
Plastic lier | Glycerln | 1.88 | 1.26 | 2.19 | 1.39 | 0.47 | 3.42 | 2.79 | 3.88 | 3.10 | 2.01 | 3.10 | 2.01 |
Sorbttol | 1.13 | 1.26 | 1.79 | 0.93 | 0.47 | - | - | - | 0.98 | - | 0.88 | - | |
Polyethylene glycol | - | 0.83 | 1.32 | - | - | - | - | - | 2.05 | - | 2.05 | - | |
Propylene glycol | - | - | - | 1.39 | 2.79 | - | - | - | - | 3.23 | - | 3.23 | |
Additive | Titanium dioxide | - | 0.05 | - | 0.57 | 0.55 | 0.71 | - | - | - | - | - | - |
Swecting agent | Sodium saccharin | 0.04 | 0.03 | 0.04 | 0.05 | 0.05 | 0.08 | 0.05 | 0.08 | 0.08 | 0.07 | 0.06 | 0.07 |
Sucralose | 0.04 | 0.03 | 0.04 | 0.05 | 0.05 | 006 | 0.05 | 0.08 | 0.08 | 0.06 | 0.06 | 0.06 | |
Surfactant / Dispersing agent | Potysorbate Θ0 | 0.04 | 0.05 | 0.07 | 0.35 | 0.35 | 0.37 | 0.46 | 0.27 | 0.30 | 0.40 | 0.30 | 0.40 |
oocusate sodium | 0.04 | 0.05 | 0.07 | 0.07 | 0.07 | 0.07 | 0.16 | 0.02 | 0.14 | 0.25 | 0.14 | 0.25 | |
Flavor | 0.08 | 0.05 | 0,07 | 0.08 | 0.07 | 0.08 | 0.05 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | |
Water | to 100 | to 100 | to 100 | to 100 | to 100 | to 100 | to 100 | to 100 | to 100 | to 100 | to 100 | to 100 |
The film-making solutions and films obtained in Examples l to 12 were measured for their properties, and the results thereof are shown in Table 7. The films were evaluated for their tastes and feeling of irritation, and the results thereof are shown in Table 8. For this test, ten subjects were subject to taste each film sample by melting the sample in their mouth for one minute before spîtting it out. After testing the taste and strange feeling of one sample, each subject was to rinse their mouth with water. Testing was performed with 30 minute intervals between the samples. The rating for each sample was based on a l to 4 scale wherein l represents very bad taste or strange feeling; 2, bad taste or strange feeling; 3, moderate taste or strange feeling; and 4, very good taste or strange feeling, and the sum of the scales rated is shown in Table 8.
Table 7
Exemple | ||||||||||||
1 | 2 | 3 | 4 | 5 | 8 | 7 | 8 | 8 | 10 | 11 | 12 | |
Viscosity of Rlm-msldng solution (cp) | 8500- 8000 | 80008500 | 80008500 | 8000- 8500 | 7500- 8000 | 80008500 | 7000- 7500 | 5500- 6000 | 50005500 | 5000- 5500 | 5000- 5500 | 50005500 |
Dispersing stability of Alm-maklng solution (1wk) | Loyer sépara ti on | Loyer separati on | Loyer eparati on | Slow particle agglomc ration | Good | Loyer separati on | Good | Good | Good | Good | Good | Good |
Film Properties | not flexible/ partial agglomc ration | wrinkte/r ough | not flexible/ partial agglomc ration | wrlnMe/c rack/rou Oh | wrlnklc/c mek/rou oh | wrinklc/ not flexlble/t ardy dlslntcgr aüon | very flexible/ qulck dlslntcgr atlon | flexible/ qulck dlslntogr atlon | very flexible/ qulck dlalntcgr atlon | very flexible/ qulck dlalntcgr atlon | very flexible/ qulck dlslntcgr atlon | very flexible/ qulck dlslntcgr atlon |
Resuit | unacccp table | unacccp table | unaccep table | unaccep table | relatively good | unacccp table | very goocl | very good | very good | very good | very good | very good |
Table 8
Tes! | Example | |||||||||||
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | |
Taste | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 13 | 11 |
Feellng of Inflation | 12 | 12 | 11 | 25 | 40 | 22 | 40 | 40 | 40 | 40 | 40 | 40 |
As shown in Table 7, the film-making solutions having similar particle size of Examples 5, 7, 8, 9 and 10 not only exhibited a low viscosity but also good dispersing 10 stability of the sildenafil free base particles which were dispersed but not dissolved, as well as flexibility providing good handling stability and were not prone to breaking, and also were suitable to oral administration due to the fast melting thereof.
Furthermore, as shown in Table 8, the film préparations having similar particle size of Examples 5, 7, 8, 9 and 10 were subject to very favorable évaluation in the taste and irriration-feeling test in the mouth.
Claims (16)
1. A method for preparing a sildenafil free base-containing film, comprising: drying a polymer solution in which a sildenafil free base as an active ingrédient is dispersed.
2. The method according to claim l, wherein the sildenafil free base has a particle size distribution in which a particle diameter (DIO) corresponding to 10% of the distribution is 8 pm or more and a particle diameter (D90) corresponding to 90% of the distribution is 100 pm or less.
3. The method according to claim 2, wherein the sildenafil free base has a particle size distribution in which D10 is 5 pm or more and D90 is 80 pin or less.
4. The method according to claim 1, wherein a solvent used in the polymer solution comprises water in an amount of 90 wt% or more thereof so that the sildenafil free base is prevented from being dissolved.
5. The method according to claim 4, wherein the solvent used in the polymer solution comprises water in an amount of 95 wt% or more thereof so that the sildenafil free base is prevented from being dissolved.
6. A method for preparing a sildenafil free base-containing film, comprising: dispersing a sildenafil free base in a solution obtained by dissolving a polymer and a plasticizer in a solvent comprising 90 wt% or more of water, and drying the solution to form a dried film, the sildenafil free base having a particle size distribution in which D10 is 5 pm or more and D90 is 80 pm or less, wherein the polymer is used in an amount of 20 to 45 wt%, the plasticizer is used in an amount of 4 to 20 wt%, and the sildenafil free base is used in an amount of 40 to 60 wt%, based on the total weight of the dried film.
7. The method according to claim l or 6, wherein the polymer has a viscosity of 15 cp or less when measured in an aqueous solution containing 2 wt% of the polymer.
8. The method according to claim 7, wherein the polymer is a mixture of a polymer having a viscosity of 15 cp or less and a polymer having a viscosity of 50 cp or more, each viscosity being measured in an aqueous solution containing 2 wt% of each polymer.
9. The method according to claim 8, wherein the polymer comprises pullulan, propylene glycol alginate and xanthan gum.
10. The method according to claim l or 6, wherein the solution further comprises a surfactant, a dispersing agent, or a mixture thereof
11. The method according to claim l or 6, wherein the polymer comprises pullulan.
12. The method according to claim l or 6, wherein the solvent is used in an amount of 1.3 to 3.3 parts by weight based on l part by weight of the components of the film remained after drying.
13. A sildenafil free base-containing film, comprising a sildenafil free base uniformly dispersed in a film comprising pullulan as a polymer, the sildenafil free base having a particle size distribution in which a particle diameter (DIO) corresponding to 10% of the distribution is 8 pm or more and a particle diameter (D90) corresponding to 90% of the distribution is 100 pm or less.
14. The sildenafil free base-containing film according to claim 13, which comprises glycérine as a plasticizer.
15. The sildenafil free base-containing film according to claim 14, which further comprises a surfactant, a dispersing agent, or a mixture thereof
16. The sildenafil free base-containing film according to claim 13, wherein the
5 polymer comprises pullulan, propylene glycol alginate and xanthan gum.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2011-0012516 | 2011-02-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA16526A true OA16526A (en) | 2015-10-22 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9907759B2 (en) | Sildenafil-free base-containing film preparation and method for producing same | |
JP2013527164A (en) | Solid oral dosage form containing tadalafil | |
US9603797B2 (en) | Oral and/or buccal composition in the form of a thin film of a weakly soluble active ingredient, method of preparing same and use of same | |
KR102223105B1 (en) | Film formulation containing tadalafil free base comprising polyethylene glycol based polymer and/or vinylpyrrolidone base polymer as dispersing agents | |
Gupta et al. | Enhancement of dissolution rate of rapidly dissolving oral film of meclizine hydrochloride by complexation of Meclizine hydrochloride with ß-cyclodextrine | |
EP2995301B1 (en) | Film preparation containing donepezil-free base and method for producing same | |
US20120149713A1 (en) | Oral films comprising 7-[4-[4-(2,3-dichlorophenyl) piperazin-1-l]butoxy]-3,4-dihydro-1h-quinolin-2-one base or salts or hydrates thereof | |
OA16526A (en) | Sildenafil-free base-containing film preparation and method for producing same. | |
US11116769B2 (en) | Tadalafil free base-containing film dosage form containing polyethylene glycol-based polymer and/or vinyl pyrrolidone-based polymer as dispersion stabilizer | |
KR100958138B1 (en) | A Pharmaceutical Composition Comprising Megestrol Acetate with Great Stability and the Preparing Method Thereof | |
CN116036050B (en) | Vonoprazol fumarate oral film-dissolving agent and preparation method thereof | |
CN107823160B (en) | Solid dispersion preparation for resisting gout and preparation method thereof | |
CN118059070A (en) | Loratadine oral film-dissolving agent and preparation method thereof | |
WO2021132565A1 (en) | Aqueous suspension composition containing sirolimus or salt thereof | |
CN107823191A (en) | A kind of 9-hydroxy-risperidone orally instant film preparation and its preparation technology |